Brief: ABVC BioPharma Says Phase II Vitargus Clinical Study Protocol Gets Local Ethics Committee Approval
02/08/2022 14:25
Aug 2 (Reuters) - ABVC Biopharma Inc ABVC.O :
* ABVC BIOPHARMA PROVIDES VITARGUS® UPDATE
* ABVC BIOPHARMA INC - PHASE II VITARGUS CLINICAL STUDY
PROTOCOL
RECEIVES LOCAL ETHICS COMMITTEE APPROVAL
* ABVC BIOPHARMA INC - VITARGUS PHASE II CLINICAL STUDY
PROTOCOL
DOCUMENTS ARE NOW UNDER REVIEW BY AUSTRALIAN BELLBERRY HUMAN
RESEARCH ETHICS COMMITTEE
* ABVC BIOPHARMA INC - UPON TGA APPROVAL, CLINICAL TRIAL
WILL
BEGIN IN AUSTRALIA AT PREVIOUSLY SELECTED SITES
Source text for Eikon: ID:nGNX8SyKDJ
Further company coverage: ABVC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon
Brief: Abvc Biopharma Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
Brief: ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma
Brief: ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products Partner